CompletedNot Applicable

Drug Use Surveillance of Takecab for "Supplement to Helicobacter Pylori Eradication"

Japan560 participantsStarted 2015-09-01

Plain-language summary

The purpose of this study is to evaluate the safety and efficacy on participants receiving first-line eradication and second-line eradication including vonoprazan (Takecab) tablets (triple therapy) in the routine clinical setting.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Participants receiving H. pylori eradication treatment for the first time * Participants for whom H. pylori eradication with Takecab tablets or proton pump inhibitor + amoxicillin + clarithromycin was found unsuccessful and who will receive eradication treatment with amoxicillin and metronidazole Exclusion Criteria: * Participants with previous history of hypersensitivity to ingredients in Takecab tablets * Participants taking atazanavir sulfate or rilpivirine hydrochloride

What they're measuring

Percentage of Participants Who Had One or More Adverse Drug Reactions

Timeframe: Up to 7 days and 2 months

Trial details

NCT IDNCT03219723

SponsorTakeda

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2017-04-30

Results submitted2018-04-27

View on ClinicalTrials.gov More Gastric/Duodenal Ulcer, Gastric MALT Lymphoma, Idiopathic Thrombocytopenic Purpura, or H. Pylori Gastritis, and Other trials